Qtonic Quantum | Post-Quantum Ready, Continuously™ | May 2026
When the OCR auditor asks for your post-quantum migration plan, what do you point to?
A regulator-aligned readiness brief for health systems, integrated delivery networks, medical device manufacturers, payers, and research hospitals.
Revised for CISO, CMIO, GC, Head of Quality, and CMO discussion | May 2026
Executive Thesis
The audit question is evidentiary, not aspirational
Healthcare organizations do not need to predict a single CRQC date. They need to demonstrate cryptographic governance under the same HIPAA Security Rule expectations they already meet for encryption-at-rest and in-transit, breach notification, and business associate oversight. If protected health information, implantable device firmware, genomic records, or clinical trial data must remain confidential and integrity-bound past 2030, the organization needs a cryptographic inventory, named owners, and a migration sequence — documented now.
The Problem
Long-retained medical records, pediatric records held to age 21+, genomic data with perpetual sensitivity, and 5-to-15-year fielded device firmware often outlive the public-key cryptography protecting them.
The Gap
HIPAA Risk Analyses and HITRUST attestations grade present configuration. They do not grade future decryptability under a cryptographically relevant quantum computer.
The Move
Begin with QScout on an authorized public domain. Escalate to QStrike or QSolve only where evidence justifies deeper proof or migration governance.
Source: Qtonic Quantum services and QScout public pages | Risk framing for executive review
Why Now
The 2029 deadline meets HIPAA addressable encryption
The standards are finalized. The supervisory backdrop is tightening. Health systems and device manufacturers that move first will have dated evidence the next OCR audit, FDA pre-submission review, or HITRUST cycle can verify. Dates below are planning anchors drawn from public government guidance — not binding legal deadlines, except where regulators have explicitly cited them.
August 2024
NIST finalizes the first PQC FIPS standards: ML-KEM (FIPS 203), ML-DSA (FIPS 204), and SLH-DSA (FIPS 205). Federal procurement, the VA, IHS, and the largest health systems begin formal migration scoping.
September 2023
FDA issues final guidance on Cybersecurity in Medical Devices, codifying premarket expectations for SBOMs, vulnerability handling, and cryptographic agility planning across the device lifecycle.
April 2024
FDA cybersecurity refusal-to-accept authority becomes operational. Premarket submissions that do not meet section 524B of the Federal Food, Drug, and Cosmetic Act may be refused on cybersecurity grounds.
2024 (HHS CPGs)
HHS publishes voluntary Cybersecurity Performance Goals for the Healthcare and Public Health Sector. A pending mandatory framework is signaled for hospitals participating in Medicare and Medicaid.
2030 (planning anchor)
NIST IR 8547 (Initial Public Draft) signals 2030 as the deprecation milestone for quantum-vulnerable public-key algorithms in federal systems. OCR enforcement and HITRUST control mappings frequently align with NIST direction. (Non-binding planning anchor)
2035 (planning anchor)
NIST IR 8547 identifies 2035 as the disallowance horizon for quantum-vulnerable algorithms. Long-retained medical records, genomic vaults, and fielded implantable device firmware must be migrated well before this anchor to avoid HNDL exposure on still-confidential material.
The gap between the finalized standards and the audit-ready evidence record is the window every covered entity and device manufacturer must close. The first OCR audit question is rarely “are you done?” — it is “what is your dated plan, and who owns it?”
Sources: NIST FIPS 203/204/205 (Aug 2024), NIST IR 8547 IPD, FDA Cybersecurity in Medical Devices final guidance (Sep 2023), FD&C Act section 524B, HHS Cybersecurity Performance Goals (2024) | Dates are planning anchors, not binding migration deadlines
Regulatory Alignment
Six regulators. One consistent expectation: documented cryptographic governance.
No single regulator has issued a binding PQC migration mandate for the private healthcare sector. Read together, the supervisory record already expects what a credible quantum-readiness program produces: an inventory, an owner, a plan, and dated evidence. The table below summarizes what each authority publishes today — and what the organization should be ready to point to.
| Authority | Public Anchor | What It Expects |
|---|---|---|
| HHS OCR (HIPAA) | 45 CFR § 164.312 Security Rule; 45 CFR §§ 164.400-414 breach notification; 45 CFR § 164 Subpart E Privacy Rule | Encryption-at-rest and in-transit as addressable specifications; breach notification within 60 days of discovery; documented Risk Analysis and Risk Management plan covering ePHI confidentiality and integrity. |
| NIST | FIPS 203/204/205; IR 8547; SP 800-66r2 (HIPAA Security Rule implementation guidance) | Adopt ML-KEM, ML-DSA, SLH-DSA. Deprecate quantum-vulnerable public-key algorithms by 2030; disallow by 2035. SP 800-66r2 ties HIPAA Security Rule controls to NIST cryptographic baselines. |
| FDA | Cybersecurity in Medical Devices final guidance (Sep 2023); FD&C Act § 524B (Apr 2024) | Premarket SBOMs, vulnerability handling, cryptographic agility planning, and post-market security update commitments across the device lifecycle. Refusal-to-accept authority for non-compliant submissions. |
| ONC | Health IT certification criteria (45 CFR Part 170); USCDI v3; encryption test procedures | Certified EHR technology must demonstrate encryption controls for stored ePHI and authentication, and meet interoperability and integrity requirements aligned with USCDI and FHIR R4. |
| HHS CPGs | Healthcare and Public Health Sector Cybersecurity Performance Goals (2024) | Voluntary essential and enhanced goals on encryption, MFA, vendor cybersecurity, incident planning, and asset inventory. Pending mandatory framework signaled for Medicare/Medicaid participants. |
| HITRUST | HITRUST CSF e1, i1, r2 control mappings | Cryptographic controls mapped across e1 (foundational), i1 (leading practice), and r2 (expanded) levels, with attestation evidence acceptable to payers, hospital systems, and business associates. |
Qtonic Quantum risk framing — not legal or regulatory advice: This summary is an interpretation of foreseeable supervisory expectation. Specific obligations vary by entity type, covered status, jurisdiction, and the presence of business associate agreements. Organizations should obtain independent counsel on their applicable rules.
Sources: 45 CFR Parts 164 and 170, NIST IR 8547 IPD, NIST SP 800-66r2, FDA Cybersecurity in Medical Devices final guidance, FD&C Act section 524B, HHS CPGs (2024), HITRUST CSF | Public anchors only
The HNDL Clock
Harvest now, decrypt later changes the breach window for healthcare
The adversary does not need a quantum computer today to create a confidentiality problem today. Encrypted material captured now may become readable later if it relies on RSA, ECDH, or ECDSA — and must remain confidential beyond the migration horizon. Healthcare has the longest tail of any regulated sector.
Medical Records and PHI
Adult medical records are typically retained six to ten years under state law. Pediatric records are commonly held to age 21 or beyond — a 21-year HNDL window for a newborn admitted today.
Genomic Data
Whole-genome sequence data is effectively perpetual in sensitivity. It can re-identify family members across generations and cannot be rotated, revoked, or replaced after exposure.
Implantable Device Firmware
Insulin pumps, pacemakers, neurostimulators, and CGMs are fielded for 5 to 15 years. Cryptographic keys baked into firmware at manufacture sit inside patients past every migration deadline.
HIE and Telehealth Traffic
Cross-organization HIE messaging and telehealth session encryption rely on long-lived asymmetric keys. Captured-now traffic may be decryptable or forgeable against future signature-validation gaps.
Sources: 45 CFR Part 164, state medical-records retention statutes, FDA total product life cycle guidance, Global Risk Institute Quantum Threat Timeline 2024 | HNDL framing for buyer discussion
QScout
What QScout proves: external cryptographic posture, mapped to HIPAA Security Rule §§ 164.308 / .312
QScout converts an authorized public domain into board-grade signal in a week. The deliverable is structured to align with the encryption-control and risk-analysis questions an OCR auditor or HITRUST assessor already asks.
QScout Free Public Scan
- One authorized public domain and business email verification
- External TLS, DNS, HTTP, certificate, and surface metadata
- Browser-safe executive snapshot
- Clear recommendation for next step
What It Answers
- What is externally visible to the OCR auditor’s reviewer today?
- Where is HNDL exposure observable on patient-facing portals and APIs?
- Which HIPAA control owner takes the finding next?
Surface / Silver / Gold Progression
- QScout Surface all-approved-public-domain review without credentials
- QScout Silver approved credentialed paths and application evidence
- QScout Gold privileged evidence bundles and CBOM handoff
- Operator-led scope and HIPAA control-owner review
HIPAA Mapping
Findings are organized to support the HIPAA Security Rule administrative safeguards (45 CFR § 164.308) and technical safeguards (45 CFR § 164.312) — reducing back-and-forth at audit time and producing artifacts the Risk Analysis can directly cite.
Sources: Qtonic Quantum QScout page, Legal & Privacy page, 45 CFR § 164.308 and § 164.312, NIST SP 800-66r2
QStrike
What QStrike proves: cryptographically signed evidence before migration spend accelerates
QStrike sits between cryptographic discovery and migration commitment. It validates which attack paths against the organization’s actual cryptographic surface are real — before procurement signs a multi-year EHR, payer, or device-fleet remediation plan.
1
Forward-Threat Validation
Validation runs against the organization's observed cryptographic surface — not generic healthcare profiles — with provider-aligned workflows and confidence-weighted findings.
2
Cryptographically Signed Evidence
Findings ship with cryptographic signatures and a verification path suitable for regulated diligence.
3
$2M Challenge — QStrike only
$2M Challenge — Subject to Terms. Qualifying QStrike engagements may be eligible for a $2M payout if zero high or critical cryptographic vulnerabilities are found after independent review. Eligibility is subject to signed challenge terms, defined scope, exclusions, an independent review process, and a program cap. The challenge applies to QStrike only — not to QScout. See qtonicquantum.com for full terms.
Sources: Qtonic Quantum QStrike page and $2M Challenge page | NIST FIPS 204 (ML-DSA)
QSolve
What QSolve fixes: vendor crypto-agility for EHR, medical device, and payer ecosystems
Post-quantum readiness in healthcare fails at the vendor seam. EHR platforms, PACS and imaging archives, KMS providers, identity systems, HIE gateways, and medical device manufacturers are where the cryptographic agility gap is widest. QSolve converts evidence into governed execution with named owners and business associate agreement implications surfaced.
01
Evidence-Led Sequencing
Migration order is driven by measured exposure, validated risk, and implementation dependencies — not vendor convenience or release-train politics.
02
Vendor Crypto-Agility
Cipher-suite migration roadmaps are built against actual EHR, device, and HIE vendor capability, not slide-deck PQC claims. Independent attestation paths sit alongside vendor commitments.
03
Buyer-Controlled Structure
Solution choices remain accountable to the organization's own requirements. No single EHR or device-platform vendor's positioning shapes the migration architecture.
04
Control-Owner Clarity
Decisions, handoffs, and implementation responsibility are explicit at every step — eliminating accountability gaps OCR investigators and HITRUST assessors will probe.
05
Validation Closure
Post-migration follow-through ties back to the original evidence chain, confirming what was fixed, what remains open, and what the next OCR audit or FDA post-market review will see.
Decision support covers ML-KEM, ML-DSA, and SLH-DSA adoption tied to measured exposure across EHR, PACS, identity, HIE, telehealth, payer-claims, and medical device firmware surfaces.
Source: Qtonic Quantum QSolve page
OCR Audit Walkthrough
An OCR audit scenario: what an investigator asks, what you point to
The following walkthrough is an illustrative composite based on public OCR audit protocols and HITRUST assessment practice. It is not a transcript and does not describe any specific organization.
Investigator
“Walk me through your Risk Analysis. What encryption protects ePHI in transit and at rest, who owns each control, and how is post-quantum exposure documented?”
What you point to
QScout Free dated executive signal plus QScout Silver or Gold cryptographic bill of materials covering TLS, KMS, IAM, EHR APIs, patient portals, and HIE gateways when approved — with named control owners mapped to 45 CFR § 164.308 and § 164.312.
Investigator
“How are you preparing for the NIST post-quantum transition? What is your cryptographic agility roadmap?”
What you point to
QSolve dated migration sequence aligned to FIPS 203/204/205 adoption windows, with EHR and device vendor crypto-agility attestations and control-owner sign-offs.
Investigator
“How do you validate vendor cryptographic claims independently of the BAA?”
What you point to
Q-Lab independent scoring across 10 published dimensions, plus QStrike forward-threat validation reports with cryptographic signatures — supporting the Risk Analysis without relying on vendor self-attestation.
Illustrative only. This walkthrough is a composite of public OCR audit protocols and HITRUST practice notes. Not a transcript, not a prediction of any specific audit outcome.
Sources: HHS OCR HIPAA Audit Protocol, NIST SP 800-66r2, HITRUST CSF assessor practice notes | Composite scenario
Implantable Device Math
Implantable device firmware migration math: the patient outlives the cipher
Implantable medical devices are the pressure point. Insulin pumps, pacemakers, neurostimulators, ICDs, and CGMs ship with cryptographic keys at manufacture, are surgically placed inside patients, and remain in service for 5 to 15 years. The data does not need to stay confidential forever — but command-authentication and firmware-signing integrity guarantees must survive the migration window without explant.
1
Field Service Life
Pacemakers and ICDs are commonly implanted for 7 to 12 years; neurostimulators for 5 to 10 years. Firmware signed with ECDSA-P256 today must remain trustworthy across the entire field life.
2
Migration Time
Cryptographic agility design changes, FDA pre-submission cycle, manufacturing requalification, OTA update infrastructure, and field rollout — a multi-year program even for a single product line.
3
Time to Exposure
CRQC uncertainty combined with NIST IR 8547 deprecation (2030) and disallowance (2035) anchors sets the outer boundary of tolerable delay. Devices implanted in 2026 will still be in patients past both anchors.
When the device service life exceeds the migration window, delay creates present-day exposure. That is the harvest-now, decrypt-later equation applied to the device layer — and the reason FDA cybersecurity guidance has been raising the bar on cryptographic agility planning each cycle.
Sources: FDA Cybersecurity in Medical Devices final guidance, FD&C Act § 524B, FDA Total Product Life Cycle guidance, NIST IR 8547 IPD | Risk model for device quality and regulatory affairs review
HIE Cross-Organization Integrity
The HIE cross-organization integrity gap
HIPAA business associate expectations and ONC interoperability rules set high expectations for cross-organization message integrity. In the post-quantum context, those expectations now include the organization’s ability to independently validate — not just trust — the cryptographic posture of every HIE participant, FHIR R4 endpoint, and Direct messaging gateway it exchanges PHI with.
EHR Vendor Layer
Hospital systems depend on a small number of EHR vendors whose cryptographic roadmaps cascade across thousands of downstream organizations. Independent validation closes the asymmetry, particularly around FHIR R4 token signing and SMART-on-FHIR identity flows.
HIE and Direct Messaging
Statewide HIEs, eHealth Exchange, Carequality, and CommonWell traffic relies on long-lived asymmetric infrastructure. Captured-now traffic may be replayable or forgeable against future signature-validation gaps across organization boundaries.
Imaging and Pharmacy
PACS DICOM transfers, e-prescribing networks (Surescripts), and DEA EPCS-controlled prescription signing all sit on long-lived asymmetric infrastructure. Third-party-risk evidence must show migration-ready dependencies, not migration-promising ones.
Sources: 21st Century Cures Act information-blocking rule, ONC USCDI v3, FHIR R4 specification, DEA EPCS rules (21 CFR Part 1311), Qtonic Quantum Lab methodology
Procurement Readiness
What your vendor management team needs from us
Vendor management, BAA owners, and supply chain teams want a short, factual evidence pack that survives a third-party risk review and HITRUST update cycle. The first engagement is structured to produce exactly that.
1
Scope and Authorization
Written authorization for the named domain. Scope of access. Defined escalation criteria. Information-handling commitments. No PHI access at QScout Free.
2
Data Handling
What QScout Free touches and avoids. Where evidence is stored. Retention windows. Subprocessor list. BAA path if scope expands beyond public surface.
3
Operating Posture
Cryptographic posture of Qtonic Quantum Corp. itself, including signing keys, evidence-bundle protection, and personnel access controls.
4
Audit and Insurance
Insurance certificates on request. Engagement letters. Reproduction notes. Chain-of-custody handling for evidence delivered to the organization.
“The next OCR audit will ask whether we have a dated cryptographic inventory and a migration sequence tied to our Risk Analysis. If I cannot point to one, the corrective action plan writes itself. I would rather pre-empt that with a one-week QScout signal than improvise during fieldwork.”
Sources: Qtonic Quantum QScout Legal & Privacy page, 45 CFR § 164.308(b) business associate provisions | Composite role — not a named individual
CMIO Perspective
Integrated delivery network: EHR encryption and FHIR R4 interoperability
Integrated delivery networks live at the seam between HIPAA covered-entity obligations and ONC interoperability mandates. A CMIO must defend EHR encryption choices, FHIR R4 endpoint posture, and SMART-on-FHIR identity flows against both an OCR auditor and a clinical-systems steering committee.
EHR Encryption Surface
Stored ePHI at rest, application-tier encryption, KMS posture, and API token signing all need a dated cryptographic inventory before a credible PQC roadmap can be drafted.
Interoperability Layer
FHIR R4 endpoints, USCDI v3 data-class exchange, and SMART-on-FHIR OAuth 2.0 / OIDC flows depend on signature schemes that all need explicit cryptographic-agility planning.
Clinical Steering Defense
A CMIO needs evidence the steering committee can endorse without a six-month vendor-RFI cycle. QScout and Q-Lab outputs sit in front of that committee as defensible, dated artifacts.
“My steering committee will not sign off on a multi-year EHR cryptographic refresh based on vendor slideware. I want a dated assessment, named control owners, and an independent score I can stand behind in front of the medical executive committee.”
Sources: 45 CFR § 164.312, ONC USCDI v3, FHIR R4 specification, SMART-on-FHIR App Launch | Composite role — not a named individual
CISO Perspective
Regional health system: HIPAA Security Rule + breach notification cycle
A CISO at a regional health system manages a cryptographic estate that spans on-premises EHR, hosted PACS, third-party patient portals, and vendor pharmacy systems. The Security Rule sets the floor; the breach notification clock sets the consequence of getting it wrong.
Risk Analysis Anchor
45 CFR § 164.308(a)(1)(ii)(A) requires an accurate and thorough Risk Analysis. PQC exposure is now a reasonably anticipated threat that the Risk Analysis must address.
60-Day Breach Clock
45 CFR §§ 164.400-414 set a 60-day disclosure window from discovery. If long-retained PHI becomes decryptable later, the discovery and notification math is unforgiving.
Business Associate Chain
BAAs cascade Security Rule obligations to subcontractors. Documented post-quantum diligence at the covered-entity layer is what every BA review will increasingly probe.
“The 60-day breach clock is what concentrates my mind. If our Risk Analysis does not address post-quantum exposure on long-retained PHI, every later finding writes itself into a corrective action plan. A dated QScout signal is the cheapest way to get ahead of that conversation.”
Sources: 45 CFR §§ 164.308, 164.312, 164.400-414, NIST SP 800-66r2 | Composite role — not a named individual
Medical Device Readiness Path
Medical device manufacturer path: FDA pre-submission and post-market crypto-agility
Medical device manufacturers must defend cryptographic agility planning across the total product life cycle. FDA section 524B refusal-to-accept authority, premarket SBOM expectations, and post-market vulnerability handling all sit inside the FDA Cybersecurity in Medical Devices final guidance. The Head of Quality owns the evidence chain.
Day 0 — Authorization
Agree authorized public domain (corporate marketing surface, customer portal, OTA-update endpoints), executive sponsor, and escalation criteria. No scanning before written authorization.
Week 1 — QScout Free
Produce browser-safe executive signal on customer-facing surface, including OTA-update infrastructure, customer portals, and HCP-facing systems. Map findings to the device cybersecurity threat model.
Weeks 2-6 — Pre-Submission Evidence
Use QScout Surface or Silver plus Q-Lab scoring to assemble cryptographic-agility evidence suitable for FDA pre-submission discussion and post-market vulnerability disclosure cycles.
Quarterly — QScout Pulse
Continuous post-quantum drift intelligence between major submission cycles. Detect posture drift before the next pre-submission interaction or post-market review.
When evidence supports it
Escalate to QStrike for forward-threat validation against fielded firmware update infrastructure and HCP integration surface, or QSolve for governed cryptographic agility migration.
“Section 524B is operational. My pre-submission packets need cryptographic-agility evidence that a reviewer can verify, not a paragraph of forward-looking statements. I would rather have a dated independent assessment in the dossier than scramble during the next interaction.”
Sources: FDA Cybersecurity in Medical Devices final guidance (Sep 2023), FD&C Act § 524B (Apr 2024), FDA Total Product Life Cycle guidance | Composite role — not a named individual
Payer Readiness Path
Payer readiness path: claims, member data, and 42 CFR Part 2 segmentation
Health plans and payers operate at the intersection of HIPAA, state insurance regulation, and 42 CFR Part 2 substance-use-disorder confidentiality. Claims data, member portals, broker channels, and provider network APIs all sit on quantum-vulnerable cryptography today. General Counsel owns the segmentation story.
1
Discovery Depth
QScout Surface or Silver against authorized scope across member portals, provider APIs, broker channels, and claims-clearinghouse interfaces.
2
42 CFR Part 2 Overlay
Substance use disorder records require segmentation and stricter consent. Cryptographic boundaries between Part 2 and general PHI must be evidenced, not assumed.
3
State Law Stack
CCPA medical extension, NY SHIELD Act, and TX Medical Records Privacy Act each layer additional encryption and breach notification expectations on member data.
4
QScout Pulse
Continuous between-cycle drift intelligence covering external, vendor, and authorized internal surfaces — sized to the payer's broker and provider ecosystem.
“My segmentation story for 42 CFR Part 2 records depends on cryptographic boundaries that need to hold for decades. The post-quantum question is not theoretical for me — it is the next state attorney general inquiry waiting to happen.”
Sources: 42 CFR Part 2, CCPA medical extension, NY SHIELD Act, TX Medical Records Privacy Act, 45 CFR Part 164 | Composite role — not a named individual
Research Hospital Readiness Path
Research hospital path: clinical trial integrity and the genomic vault
Research hospitals carry a unique HNDL profile: clinical trial datasets must remain integrity-bound for decades, genomic vaults are perpetual in sensitivity, and IRB-approved studies cross institutional boundaries. The Chief Medical Officer owns the trial-integrity story; the GC owns the consent and re-identification story.
1
Clinical Trial Dataset Integrity
21 CFR Part 11 e-records and e-signatures must survive long after the trial closes. ECDSA-signed audit trails captured today must remain verifiable past 2035.
2
Genomic Vault Confidentiality
Whole-genome sequence data is effectively perpetual. It cannot be revoked, rotated, or replaced if exposed. PQC-grade encryption for genomic vaults is the only durable answer.
3
Multi-Site Study Cryptography
Cross-institutional trial collaboration relies on long-lived public-key infrastructure for data exchange and identity. Quantum-vulnerable links anywhere in the chain become the weakest point.
4
Consent and Re-Identification
Genomic data can re-identify family members across generations. The consent narrative depends on a cryptographic confidentiality story that holds for the lifetime of the descendants.
“The trial dataset I authorize today will be reanalyzed by my successors twenty years from now. If the cryptographic chain of custody breaks somewhere in the middle, the whole record loses evidentiary weight. I want that risk closed before it becomes a corrective action plan.”
Sources: 21 CFR Part 11, NIH genomic data sharing policy, Common Rule (45 CFR 46), NIST IR 8547 IPD | Composite role — not a named individual
FAQ
Frequently asked questions
- What does HIPAA addressable mean, and how is it different from required?
- Under 45 CFR § 164.306(d), implementation specifications are either required or addressable. Addressable does not mean optional. The covered entity must assess whether the specification is reasonable and appropriate, and either implement it, implement an equivalent measure, or document why neither is needed. Encryption-at-rest and in-transit (§ 164.312) are addressable, but the documented justification is the artifact OCR examines.
- What is the FDA SBOM scope for medical devices?
- Premarket submissions for cyber devices under FD&C Act § 524B are expected to include a software bill of materials, vulnerability handling plans, and cryptographic agility provisions across the total product life cycle. The FDA Cybersecurity in Medical Devices final guidance (Sep 2023) is the operative reference.
- What does QScout Free actually catch on PHI surfaces?
- QScout Free covers external surface — TLS configuration, certificate posture, DNS hygiene, HTTP headers, and visible cryptographic primitives on patient portals, FHIR endpoints, and corporate marketing surface. It does not touch ePHI itself. Surface, Silver, and Gold expand scope only by written authorization.
- How does this overlap with HITRUST CSF e1, i1, or r2?
- QScout findings map to HITRUST cryptographic controls across all three levels. e1 covers foundational hygiene; i1 covers leading practice; r2 covers expanded assurance. The artifacts QScout produces are designed to slot into the assessor's evidence request without translation.
- What are the BAA implications of engaging Qtonic Quantum?
- QScout Free is structured to operate on public surface only and does not require a BAA. If scope expands beyond public surface and the organization expects PHI to be reachable, a BAA path is established before that work begins. The default posture is to avoid PHI exposure entirely.
- Does telehealth fall in scope?
- Yes. Telehealth session encryption sits on the same long-lived asymmetric infrastructure as the rest of the patient-portal stack. QScout examines telehealth-facing surface where it is part of the authorized public domain.
- What does breach notification math look like if PQC migration is delayed?
- If long-retained PHI is decrypted later under future cryptographically relevant quantum capability, the breach is discovered at decryption — and the 60-day clock under 45 CFR § 164.404 starts then. The corrective action posture is materially worse if the Risk Analysis did not address PQC exposure.
- Does the $2M challenge apply to QScout?
- No. The $2M challenge applies to QStrike engagements only, and is subject to signed challenge terms, scope conditions, exclusions, an independent review process, and a program cap. QScout findings are not in scope. See qtonicquantum.com for full terms.
- How does this interact with DEA EPCS for controlled substances?
- DEA EPCS rules (21 CFR Part 1311) require cryptographic signing of controlled-substance prescriptions. The signature schemes in operational use today are quantum-vulnerable. A QScout or QStrike engagement produces evidence relevant to EPCS cryptographic posture, but does not replace DEA audit obligations.
- Is this legal or regulatory advice?
- No. The content on this page is Qtonic Quantum's risk interpretation of public regulatory anchors. It is not legal, tax, or regulatory advice. Organizations should consult qualified counsel on specific obligations.
Qtonic Quantum | Buyer FAQ for healthcare | Not legal or regulatory advice
Methodology and Reference Material
Methodology, Field Book, Buyer’s Guide, and category framing
The methodology page documents how QScout converts an authorized public domain into evidence-grade findings, including scope handling, evidence capture, and chain-of-custody. The Field Book and Buyer’s Guide are written for diligence teams that want to evaluate Qtonic Quantum against published criteria, not slideware.
Field Book →
Operator-grade reference for security and infrastructure teams. Methodology-first, evidence-bound, no marketing language.
QScout Buyer’s Guide →
Procurement-grade questions, scope language, and diligence checklist for evaluating QScout against alternative offerings.
Procurement and security teams often ask “who else is in the category?” The closest public reference point is incident-response and proactive-services delivery — applied to cryptographic posture rather than active intrusion. The category-comparison page covers what carries over, what does not, and what is genuinely new.
Source: Qtonic Quantum QScout methodology, Field Book, QScout Buyer’s Guide, category-comparison page
Audit Decision
Authorize one domain.
Leave with a dated signal.
One authorized domain. One week. One executive-grade number that tells the board, the next OCR auditor, and your HITRUST assessor where you stand.
The evidence tells you what comes next — not the vendor.
qtonicquantum.com | +1 (866) 4-QTONIC
Related Industries
Stay updated
Appendix
Sources and References
Public sources used to harden claims and update product positioning. All product claims are based on Qtonic Quantum public pages available during review. Regulatory anchors below are public-domain only; URLs are provided for verification and not as endorsements.
Qtonic Quantum Sources
- Qtonic Quantum homepage and Services page
- QScout product page and Legal & Privacy page
- QScout methodology page
- QScout Buyer’s Guide
- QScout Pulse product page
- QStrike product page and $2M Challenge page
- QSolve product page
- Q-Lab methodology page
- Field Book
Regulatory and Standards Sources
- NIST FIPS 203 (ML-KEM), FIPS 204 (ML-DSA), FIPS 205 (SLH-DSA), Aug 2024 — csrc.nist.gov
- NIST IR 8547 Initial Public Draft — deprecation 2030, disallowance 2035 — csrc.nist.gov
- NIST SP 800-66r2 — Implementing the HIPAA Security Rule — csrc.nist.gov
- HIPAA Security Rule, 45 CFR § 164.312 — encryption-at-rest and in-transit addressable specifications — ecfr.gov
- HIPAA Privacy Rule, 45 CFR Part 164 Subpart E — ecfr.gov
- HHS OCR Breach Notification, 45 CFR §§ 164.400-414 — 60-day disclosure window — hhs.gov
- HHS Cybersecurity Performance Goals (2024) — voluntary essential and enhanced — hhs.gov/cybersecurity
- FDA Cybersecurity in Medical Devices final guidance (Sep 2023) — fda.gov
- FD&C Act § 524B and refusal-to-accept authority (Apr 2024) — fda.gov
- ONC Health IT certification criteria, 45 CFR Part 170, USCDI v3 — healthit.gov
- HITRUST CSF e1, i1, r2 control mappings — hitrustalliance.net
- DEA EPCS rules, 21 CFR Part 1311 — deadiversion.usdoj.gov
- 42 CFR Part 2 substance use disorder records confidentiality — ecfr.gov
- 21 CFR Part 11 e-records and e-signatures — ecfr.gov
- CCPA medical extension; NY SHIELD Act; TX Medical Records Privacy Act — state codes
- FHIR R4 specification, HL7 International — hl7.org/fhir
- Global Risk Institute Quantum Threat Timeline Report 2024
Regulatory and standards content is provided for business discussion purposes only and does not constitute legal, tax, or regulatory advice. Recipients should consult qualified counsel on their specific obligations. Buyer roles cited in this page are composite illustrations and do not refer to any specific named individuals or organizations.
Qtonic Quantum | Post-Quantum Ready, Continuously™ | Reference appendix
Legal and Confidentiality Notice
1. Confidentiality. This presentation and the information contained herein are confidential and proprietary to Qtonic Quantum Corp. This material is furnished solely for the purpose of evaluating a potential business relationship and may not be reproduced, disclosed, or distributed to any third party, in whole or in part, without the prior written consent of Qtonic Quantum Corp.
2. Authorized Recipients. This presentation is intended solely for the named recipient or the authorized representative of the receiving organization. Receipt by any other person does not constitute authorization to review, retain, or act upon its contents.
3. No Offer or Solicitation. Nothing in this presentation constitutes an offer to sell, a solicitation of an offer to buy, or a commitment of any kind. This material is informational only and does not create any binding obligation on the part of Qtonic Quantum Corp. or any of its affiliates.
4. No Legal, Regulatory, or Clinical Advice. This presentation does not constitute legal, tax, regulatory, or clinical advice. Recipients are responsible for obtaining independent advice from qualified counsel and clinical authorities before taking any action in reliance on the information presented.
5. No Warranty. Security assessments and findings described herein reflect point-in-time evaluations conducted under defined scope conditions. Results are provided as-is. Qtonic Quantum Corp. makes no representation or warranty, express or implied, that the assessments identify every vulnerability or that the described posture will be maintained after the assessment date.
6. Composite Roles. Buyer roles, quotes, and scenarios on this page are composite illustrations drawn from public supervisory practice. They do not refer to any specific named individuals, organizations, or engagements.
7. Intellectual Property. © 2026 Qtonic Quantum Corp. All rights reserved. Third-party names, marks, and standards referenced herein are the property of their respective owners and are used for identification and informational purposes only.
8. Governing Law. These terms are governed by the laws of the State of Florida. Any dispute arising from the use or disclosure of this material shall be resolved exclusively in the courts of Miami-Dade County, Florida. Executed agreements between the parties may contain additional or superseding terms.
Qtonic Quantum Corp. | Post-Quantum Ready, Continuously™ | For discussion with authorized recipients only.